Good morning :)
$
₹
Innoviva Inc

Innoviva Inc

INVA

NASDAQ
Asset Logo

Innoviva Inc

INVA

NASDAQ
$20.891.13% (+0.23)
$
₹
$20.891.13% (+0.23)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $1.5B the stock is ranked 2450

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

4.79
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.21
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$4.31
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.24
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

81.19%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 1 analyst's reports

Buy
1 analyst
Hold
0 analyst
Sell
0 analyst

Analysts expect a +67.46% price upside over the next year

Current Price$20.89
Target Price$35

Company Profile

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Peers

Peers

Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
37.45
37.45
1Y Return
52.36%
52.36%
Buy Reco %
77.41
77.41
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
30.77
30.77
1Y Return
51.07%
51.07%
Buy Reco %
45.83
45.83
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
115.14
115.14
1Y Return
78.78%
78.78%
Buy Reco %
57.69
57.69
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
20.71
20.71
1Y Return
12.71%
12.71%
Buy Reco %
15.38
15.38
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
23.97
23.97
1Y Return
5.95%
5.95%
Buy Reco %
90.00
90.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Innoviva Inc 4.791.210.24
Eli Lilly and Company37.4529.351.10
Johnson & Johnson30.777.532.78

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

107.8
89.9
118
164.1
97.9
186.5
119.5
-83.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue77.49103.3589.5091.8088.63100.28107.8118.0497.99119.59
Net Income36.53-34.681.2120.33-46.5863.6889.90164.15186.59-83.42
Net Profit Margin47.13%-33.55%1.35%22.14%-52.55%63.50%83.40%139.05%190.41%-69.75%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Innoviva Inc (INVA) share price today is $20.89 as of September 15, 2026 at 1:30 AM IST. The stock touched a day high of $21.09 and a day low of $20.69.

  2. Innoviva Inc stock trades on NASDAQ under the ticker symbol INVA.

  3. Innoviva Inc's market capitalization is $1.49B as of September 15, 2026 at 1:30 AM IST.

  4. Innoviva Inc's price-to-earnings (P/E) ratio is 4.79 as of September 14, 2026.

  5. Innoviva Inc's price-to-book (P/B) ratio is 1.21 as of September 14, 2026.

  6. Yes, You can buy Innoviva Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Innoviva Inc shares in three steps: 1. Search Innoviva Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Innoviva Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Innoviva Inc (INVA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.4785 shares at the current price of $20.89.

Loading...